WO2005044194A3 - Traitement ou prevention de la neoplasie a l'aide d'un inhibiteur de la proteine hsp90 - Google Patents
Traitement ou prevention de la neoplasie a l'aide d'un inhibiteur de la proteine hsp90 Download PDFInfo
- Publication number
- WO2005044194A3 WO2005044194A3 PCT/US2004/036010 US2004036010W WO2005044194A3 WO 2005044194 A3 WO2005044194 A3 WO 2005044194A3 US 2004036010 W US2004036010 W US 2004036010W WO 2005044194 A3 WO2005044194 A3 WO 2005044194A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- neoplasia
- hsp90 inhibitor
- prevention
- treatment
- inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US51522503P | 2003-10-28 | 2003-10-28 | |
US60/515,225 | 2003-10-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005044194A2 WO2005044194A2 (fr) | 2005-05-19 |
WO2005044194A3 true WO2005044194A3 (fr) | 2005-07-21 |
Family
ID=34572821
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/036010 WO2005044194A2 (fr) | 2003-10-28 | 2004-10-28 | Traitement ou prevention de la neoplasie a l'aide d'un inhibiteur de la proteine hsp90 |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2005044194A2 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9402831B2 (en) | 2011-11-14 | 2016-08-02 | Synta Pharmaceutical Corp. | Combination therapy of HSP90 inhibitors with BRAF inhibitors |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2594874T3 (es) | 2004-11-18 | 2016-12-23 | Synta Pharmaceuticals Corp. | Compuestos de triazol que modulan la actividad de HSP90 |
MX2007009888A (es) | 2005-02-17 | 2007-10-16 | Synta Pharmaceuticals Corp | Compuestos para el tratamiento de trastornos proliferativos. |
WO2007021966A1 (fr) | 2005-08-12 | 2007-02-22 | Synta Pharmaceuticals Corp. | Composes pyrazoles modulant l'activite de la proteine hsp90 |
CA2618724A1 (fr) | 2005-08-18 | 2007-02-22 | Synta Pharmaceuticals Corp. | Derives d'imidazole modulant l'activite de hsp90 |
US8455658B2 (en) | 2006-01-25 | 2013-06-04 | Synta Pharmaceuticals Corp. | Thiazole and thiadiazole compounds for inflammation and immune-related uses |
US8034834B2 (en) | 2006-05-25 | 2011-10-11 | Synta Pharmaceuticals Corp. | Method for treating proliferative disorders with HSP90 inhibitors |
EP2034996A2 (fr) | 2006-05-25 | 2009-03-18 | Synta Pharmaceuticals Corporation | Composés de triazole qui modulent l'activité de la hsp90 |
CA2653332A1 (fr) * | 2006-05-25 | 2007-12-06 | Synta Pharmaceuticals Corp. | Composes de triazole qui modulent l'activite de la hsp90 |
WO2007139967A2 (fr) | 2006-05-25 | 2007-12-06 | Synta Pharmaceuticals Corp. | Composés de triazole modulant l'activité de hsp90 |
RU2498798C2 (ru) * | 2008-01-09 | 2013-11-20 | Моликьюлар Инсайт Фармасьютикалз, Инк. | Ингибиторы карбоангидразы iх |
CA2724413C (fr) * | 2008-05-15 | 2016-10-18 | Duke University | Compositions et procedes ayant trait aux composes activant le facteur de transcription de choc thermique et cibles correspondantes |
US9315449B2 (en) * | 2008-05-15 | 2016-04-19 | Duke University | Substituted pyrazoles as heat shock transcription factor activators |
AR081810A1 (es) | 2010-04-07 | 2012-10-24 | Bayer Cropscience Ag | Piridinilpirazoles biciclicos |
WO2011133520A1 (fr) | 2010-04-19 | 2011-10-27 | Synta Pharmaceuticals Corp. | Thérapie anticancéreuse à l'aide d'une combinaison d'un composé inhibiteur de hsp90 et d'un inhibiteur d'egfr |
CA2841217C (fr) | 2010-07-09 | 2018-09-25 | Metasignal Therapeutics Inc. | Nouveaux composes de sulfonamide destines a l'inhibition de la croissance tumorale metastatique |
AU2012332424A1 (en) | 2011-11-02 | 2014-06-05 | Synta Pharmaceuticals Corp. | Combination therapy of Hsp90 inhibitors with platinum-containing agents |
AU2012332421A1 (en) | 2011-11-02 | 2014-06-05 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of Hsp90 inhibitors with topoisomerase I inhibitors |
WO2015002926A1 (fr) | 2013-07-02 | 2015-01-08 | Bristol-Myers Squibb Company | Dérivés pyrido-carboxamides tricycliques servant d'inhibiteurs de rock |
TW201506024A (zh) | 2013-07-02 | 2015-02-16 | 必治妥美雅史谷比公司 | 作為有效rock抑制劑的三環甲醯胺衍生物 |
EP3039022A4 (fr) * | 2013-08-29 | 2017-08-16 | Baylor College Of Medicine | Compositions et procédés de traitement de troubles métaboliques et troubles associés au poids corporel |
WO2015057695A1 (fr) * | 2013-10-15 | 2015-04-23 | Bohan Jin | Nouvelles compositions, leurs utilisations et procédés de préparation |
US10328064B2 (en) | 2014-12-23 | 2019-06-25 | Fgh Biotech, Inc. | Compositions of fatostatin based heterocyclic compounds and uses thereof |
CN109476635B (zh) | 2016-04-29 | 2021-07-13 | Fgh生物科技公司 | 用于治疗疾病的二取代吡唑类化合物 |
CA3036195A1 (fr) | 2016-09-07 | 2018-03-15 | Fgh Biotech, Inc. | Composes de pyrazole di-substitues pour le traitement de maladies |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5739166A (en) * | 1994-11-29 | 1998-04-14 | G.D. Searle & Co. | Substituted terphenyl compounds for the treatment of inflammation |
-
2004
- 2004-10-28 WO PCT/US2004/036010 patent/WO2005044194A2/fr active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5739166A (en) * | 1994-11-29 | 1998-04-14 | G.D. Searle & Co. | Substituted terphenyl compounds for the treatment of inflammation |
Non-Patent Citations (6)
Title |
---|
CANCER, vol. 91, no. 5, 1 March 2001 (2001-03-01), pages 940 - 948 * |
DATABASE CAPLUS [online] LI J. ET AL: "Novel terphenyls as selective cyclooxgenase-2 inhibitors and orally active anti-inflammatory agents", XP002987258, accession no. stn Database accession no. (124:278412) * |
DATABASE MEDLINE [online] DUNPHY F.R. ET AL: "Induction paclitaxel and carboplatin for patients with head and neck carcinoma. Analysis of 62 patients treated between 1994 an 1999", XP002987259, accession no. STN Database accession no. (2001:198884) * |
DATABASE MEDLINE [online] KAMATE C. ET AL: "Inflammation and cancer, the mastocytoma P815 tumor model revisited: triggering of macrophage activation in vivo with pro-tumorigenic consequences", XP002987260, accession no. STN Database accession no. (2002:378417) * |
INTERNAT J CAN, vol. 100, no. 5, 10 August 2002 (2002-08-10), pages 571 - 579 * |
J MEDICINAL CHEM, vol. 39, no. 9, 1996, pages 1846 - 1856 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9402831B2 (en) | 2011-11-14 | 2016-08-02 | Synta Pharmaceutical Corp. | Combination therapy of HSP90 inhibitors with BRAF inhibitors |
Also Published As
Publication number | Publication date |
---|---|
WO2005044194A2 (fr) | 2005-05-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005044194A3 (fr) | Traitement ou prevention de la neoplasie a l'aide d'un inhibiteur de la proteine hsp90 | |
WO2005048942A3 (fr) | Polytherapie contenant un inhibiteur cox-2 et un agent antineoplasique | |
WO2005041879A3 (fr) | Association de l'inhibiteur de hsp90 et de l'inhibiteur de la phophodiesterase destinee a traiter ou prevenir la neoplasie | |
WO2005037259A3 (fr) | Procedes et compositions de prevention ou de traitement de neoplasie comprenant un inhibiteur de la cox-2 en combinaison avec un antagoniste recepteur du facteur de croissance epidermale | |
DK1373215T3 (da) | Gelanamycinderivater egnet til behandling af cancer | |
WO2005037323A3 (fr) | Methode pour inhiber une signalisation de nf-kappa b et son utilisation pour traiter et pour prevenir des maladies humaines | |
IL160420A0 (en) | Treating or preventing diabetes with cannabidiol | |
WO2007041398A3 (fr) | Traitement du cancer a l'aide d'agonistes de rxr specifiques | |
WO2005009342A3 (fr) | Methode de traitement ou de prevention de troubles dermatologiques a l'aide d'un seul inhibiteur de la cyclooxygenase-2 ou en combinaison avec un agent de traitement dermatologique, et compositions contenant ceux-ci | |
WO2000037107A3 (fr) | Procede d'utilisation d'un inhibiteur de cyclooxygenase-2 et d'un inhibiteur de metalloproteinase matricielle en tant que therapie combinee dans le traitement de la neoplasie | |
WO2004045509A3 (fr) | Methode de therapie combinee utilisant un inhibiteur de cox-2 et un modulateur du recepteur 5-ht1a | |
WO2005027993A3 (fr) | Preservation d'acces vasculaire chez des patients en hemodialyse | |
WO2000040235A3 (fr) | Traitement de l'asthme a l'aide d'inhibiteurs de mek | |
WO2002005791A3 (fr) | Therapie antitumorale combinee | |
WO2003030819A3 (fr) | Derives de tetracycline et methodes d'utilisation | |
WO2005000213A8 (fr) | Methode permettant de traiter des maladies a l'aide d'agent d'inhibition hsp90 combines a des inhibiteurs d'enzymes | |
WO2005082375A3 (fr) | Methodes permettant de traiter la cystite interstitielle et composes et compositions connexes | |
WO2004091540A3 (fr) | Methodes de traitement de la douleur et compositions associees | |
WO2005000212A8 (fr) | Procede de traitement de maladies par des agents inhibiteurs de hsp90 en combinaison avec des inhibiteurs d'exportation nucleaire | |
EP1553951A4 (fr) | Compositions contenant un inhibiteur de jnk destinees a traiter, prevenir, gerer et/ou modifier la douleur, et leurs methodes d'utilisation | |
WO2007120485A3 (fr) | Procédés de traitement de la douleur avec des alkylxanthines et des antiépileptiques et compositions à utiliser à cet effet | |
WO2003092606A3 (fr) | Inhibiteurs de cholinesterase pour prevenir les blessures causees par des produits chimiques | |
WO2004096206A3 (fr) | Combinaison therapeutique d'un inhibiteur de cox-2 et d'un inhibiteur de tace | |
WO2008016640A3 (fr) | Traitement de l'insuffisance cardiaque progressive chronique | |
WO2004017917A3 (fr) | Procede pour la prevention et/ou le traitement de l'atherosclerose |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004796761 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2004796761 Country of ref document: EP |
|
122 | Ep: pct application non-entry in european phase |